Trial Outcomes & Findings for Randomized Controlled Trial of CES for Fibromyalgia (NCT NCT04115033)
NCT ID: NCT04115033
Last Updated: 2026-05-22
Results Overview
For subjects with fibromyalgia, clinical pain was assessed in both groups using the Defense Veterans Pain Rating Scale (DVPRS), a validated measurement tool for pain, as well as analgesic consumption. Clinical pain was measured at baseline, 6 weeks following treatment, and 12 weeks following treatment completion in both groups. Mean differences were measured between the baseline score and the 12-week score. The DVPRS is a combination of several different pain scales including the VAS, verbal rating scale, FACES scale, and numerical rating scale. Measurements will be graded on a scale of 0-10 with 0 being "no pain" and 10 being "severe" or "worst pain."
COMPLETED
NA
50 participants
baseline, 6 weeks into treatment, and 12 weeks post treatment
2026-05-22
Participant Flow
Veterans were recruited through direct referrals from Atlanta VA Healthcare System physicians, and through letters and phone calls inviting them to participate following a data access request through the VA corporate data warehouse based on a diagnosis of fibromyalgia and other characteristics matching inclusion criteria for the study.
A total of 50 participants were consented for this study. Two of these participants could not begin the study due to MRI-incompatible medical device/metal implants. These two individuals were excluded from the study after initial consent and prior to randomization. A total of 48 participants were randomly allocated to treatment groups.
Participant milestones
| Measure |
True CES Device/Treatment
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
Sham CES Device/Treatment
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
|---|---|---|
|
Overall Study
STARTED
|
25
|
23
|
|
Overall Study
COMPLETED
|
17
|
16
|
|
Overall Study
NOT COMPLETED
|
8
|
7
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Randomized Controlled Trial of CES for Fibromyalgia
Baseline characteristics by cohort
| Measure |
True CES Device/Treatment
n=25 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
Sham CES Device/Treatment
n=23 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
Total
n=48 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Sex: Female, Male
Female
|
15 Participants
n=2 Participants
|
18 Participants
n=4 Participants
|
33 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=2 Participants
|
5 Participants
n=4 Participants
|
15 Participants
n=6 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Black or African American
|
17 Participants
n=2 Participants
|
15 Participants
n=4 Participants
|
32 Participants
n=6 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=2 Participants
|
8 Participants
n=4 Participants
|
15 Participants
n=6 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
24 Participants
n=2 Participants
|
23 Participants
n=4 Participants
|
47 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Age, Continuous
|
49.8 Years
n=2 Participants
|
49.4 Years
n=4 Participants
|
49.6 Years
n=6 Participants
|
|
Defense & Veterans Pain Rating Scale (DVPRS)
|
6.6 Score on scale
n=2 Participants
|
6.8 Score on scale
n=4 Participants
|
6.7 Score on scale
n=6 Participants
|
PRIMARY outcome
Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatmentFor subjects with fibromyalgia, clinical pain was assessed in both groups using the Defense Veterans Pain Rating Scale (DVPRS), a validated measurement tool for pain, as well as analgesic consumption. Clinical pain was measured at baseline, 6 weeks following treatment, and 12 weeks following treatment completion in both groups. Mean differences were measured between the baseline score and the 12-week score. The DVPRS is a combination of several different pain scales including the VAS, verbal rating scale, FACES scale, and numerical rating scale. Measurements will be graded on a scale of 0-10 with 0 being "no pain" and 10 being "severe" or "worst pain."
Outcome measures
| Measure |
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
|---|---|---|
|
Clinical Pain Change
Change at 6-Week Timepoint
|
-1.75 Change (from baseline) in DVPRS score
Standard Deviation 1.92
|
-0.97 Change (from baseline) in DVPRS score
Standard Deviation 1.74
|
|
Clinical Pain Change
Change at 12-Week Timepoint
|
-2.00 Change (from baseline) in DVPRS score
Standard Deviation 1.97
|
-1.38 Change (from baseline) in DVPRS score
Standard Deviation 1.80
|
SECONDARY outcome
Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatment (change from baseline to 12 weeks post reported)The region of interest (ROI) was the right Cerebellar 7b seed, and a 2x2 mixed ANOVA interaction was conducted with Family -Wise Error (FWE) constraints to control for multiple comparisons. Voxel threshold was set to p\<0.005 uncorrected, cluster threshold of p\<0.05 FWE corrected. A Fisher-transform z-score represents the mean connectivity values for each covariate in the model (i.e. groups) for each significant cluster. A z-score value of 0 indicates no difference in functional connectivity. Positive z-scores denote stronger, and negative z-scores weaker, connectivity with the ROI; further research is needed to determine their clinical implications and whether these changes denote a positive or negative outcome.
Outcome measures
| Measure |
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
|---|---|---|
|
Change in Rs-fcMRI Connectivity Effect Size
MNI coordinates: -22 -90 -12 (Left Occipital Fusiform Gyrus)
|
-0.0877 Fisher-transformed z scores
Standard Deviation 0.0961
|
0.0786 Fisher-transformed z scores
Standard Deviation 0.1019
|
|
Change in Rs-fcMRI Connectivity Effect Size
MNI coordinates: -16 -44 -12 (Left Lingual Gyrus)
|
-0.1214 Fisher-transformed z scores
Standard Deviation 0.0781
|
0.063 Fisher-transformed z scores
Standard Deviation 0.0787
|
|
Change in Rs-fcMRI Connectivity Effect Size
MNI coordinates: +22 -44 -06 (Right Lingual Gyrus)
|
-0.1347 Fisher-transformed z scores
Standard Deviation 0.0964
|
0.0578 Fisher-transformed z scores
Standard Deviation 0.0787
|
SECONDARY outcome
Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatmentTests of function (sit-to-stand, bicep curl, handgrip strength) was performed in both groups at baseline, 6 weeks, and 12 weeks following treatment. Mean difference was measured between baseline and 12 weeks. The sit-to-stand test tests how many full sit-to-stands a subject can perform within a 30 second interval.
Outcome measures
| Measure |
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
|---|---|---|
|
Sit-to-stand
Change at 6-Week Timepoint
|
2.16 Change (from baseline) in repetitions
Standard Deviation 2.65
|
2.41 Change (from baseline) in repetitions
Standard Deviation 2.83
|
|
Sit-to-stand
Change at 12-Week Timepoint
|
2.13 Change (from baseline) in repetitions
Standard Deviation 2.06
|
3.12 Change (from baseline) in repetitions
Standard Deviation 2.93
|
SECONDARY outcome
Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatmentTests of function (sit-to-stand, bicep curl, handgrip strength) was performed in both groups at baseline, 6 weeks, and 12 weeks following treatment. Mean difference was measured between baseline and 12 weeks. The bicep curl tests how many full bicep curls with gender specific weights (8 pounds for male, 5 pounds for female) a subject can perform within a 30 second interval. Both arms were tested.
Outcome measures
| Measure |
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
|---|---|---|
|
Bicep-curl
Change at 6-Week Timepoint (Left Arm)
|
2.00 Change (from baseline) in repetitions
Standard Deviation 4.00
|
3.41 Change (from baseline) in repetitions
Standard Deviation 4.86
|
|
Bicep-curl
Change at 6-Week Timepoint (Right Arm)
|
2.56 Change (from baseline) in repetitions
Standard Deviation 3.38
|
2.53 Change (from baseline) in repetitions
Standard Deviation 4.37
|
|
Bicep-curl
Change at 12-Week Timepoint (Left Arm)
|
3.81 Change (from baseline) in repetitions
Standard Deviation 4.86
|
4.12 Change (from baseline) in repetitions
Standard Deviation 4.47
|
|
Bicep-curl
Change at 12-Week Timepoint (Right Arm)
|
3.19 Change (from baseline) in repetitions
Standard Deviation 4.56
|
3.94 Change (from baseline) in repetitions
Standard Deviation 4.13
|
SECONDARY outcome
Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatmentTests of function (sit-to-stand, bicep curl, handgrip strength) was performed in both groups at baseline, 6 weeks, and 12 weeks following treatment. Mean difference was measured between baseline and 12 weeks. The handgrip strength test uses a dynamometer to gauge the pressure that a subject can apply with their handgrip. Both hands were tested.
Outcome measures
| Measure |
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
|---|---|---|
|
Handgrip Strength
Change at 6-Week Timepoint (Left Hand)
|
1.13 kg
Standard Deviation 5.99
|
-0.29 kg
Standard Deviation 7.67
|
|
Handgrip Strength
Change at 6-Week Timepoint (Right Hand)
|
1.52 kg
Standard Deviation 5.56
|
0.12 kg
Standard Deviation 6.82
|
|
Handgrip Strength
Change at 12-Week Timepoint (Left Hand)
|
-0.54 kg
Standard Deviation 5.23
|
-1.31 kg
Standard Deviation 9.42
|
|
Handgrip Strength
Change at 12-Week Timepoint (Right Hand)
|
0.38 kg
Standard Deviation 5.28
|
0.49 kg
Standard Deviation 7.44
|
SECONDARY outcome
Timeframe: baseline visit and 12 weeks post treatmentNIH Patient-Reported Outcomes Measurement Information System (PROMIS) measures were assessed using a validated survey created from independently validated NIH survey questions in both groups. Mean differences in T-scores were measured between the baseline visit and the 12-week visit. PROMIS measures included: PROMIS Item Bank v1.0 - Fatigue - Short Form 6a, PROMIS Item Bank v1.0 - Emotional Distress-Depression - Short Form 4a, PROMIS Item Bank v.1.0 - Emotional Distress - Anxiety- Short Form 7a. For each measure, a lower T-score represents a better clinical outcome. All of the PROMIS measures reported (Fatigue, Depression, and Anxiety) have been standardized to have a mean of 50 and an SD of 10. This standardization means that a score of 50 is the average level in the population, and any 10-point change in either direction (greater or lesser) represents one SD difference.
Outcome measures
| Measure |
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
|
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
|
|---|---|---|
|
PROMIS Change
PROMIS Item Bank v1.0 - Fatigue - Short Form 6a
|
-4.52 T-scores
Standard Deviation 7.97 • Interval 0.0 to 0.0
|
-2.61 T-scores
Standard Deviation 6.06 • Interval -0.17 to -0.03
|
|
PROMIS Change
PROMIS Item Bank v1.0 - Emotional Distress-Depression - Short Form 4a
|
-1.51 T-scores
Standard Deviation 7.65 • Interval 0.0 to 0.0
|
-2.33 T-scores
Standard Deviation 7.45 • Interval -0.35 to -0.11
|
|
PROMIS Change
PROMIS Item Bank v.1.0 - Emotional Distress - Anxiety- Short Form 7a
|
-3.11 T-scores
Standard Deviation 8.68
|
-1.57 T-scores
Standard Deviation 6.02
|
Adverse Events
True CES Device/Treatment
Sham CES Device/Treatment
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Anna Woodbury
Atlanta VA Healthcare System, Decatur, GA
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place